Hantavirus Vaccine Status (2026): What's in Trials, What's Stalled

One of the most common questions about the MV Hondius outbreak is the simplest one: is there a hantavirus vaccine? The answer in May 2026 is the same answer health officials have been giving for more than thirty years. There is no hantavirus vaccine licensed for use in the United States or the European Union. There is one product used regionally in the Republic of Korea against a different strain. Several candidates against Andes virus and Sin Nombre virus have moved through phase 1 trials, but none has finished phase 3. This article walks through the pipeline, why it has been so slow, and what is realistic to expect by 2030.

1. What does “licensed” actually mean here?

A vaccine becomes licensed when a national regulator (the FDA in the United States, the EMA in the European Union, ANMAT in Argentina, the MFDS in Korea) reviews phase 3 efficacy and safety data and authorises a commercial product for a defined indication. There is a separate, lower bar called emergency use authorisation or conditional approval, which only the COVID-19 vaccines have so far reached for a respiratory virus on a global scale.

For hantaviruses, no candidate has finished a phase 3 efficacy trial anywhere in the world. The single product in regional use, Hantavax, was licensed in Korea before modern phase 3 standards existed.

2. Hantavax (Korea, 1990) — the only product on the shelf

Hantavax is an inactivated whole-virus vaccine developed by Cha and colleagues at the Korean Institute of Health and produced by the Korea Green Cross. It was licensed in Korea in 1990 against Hantaan virus, the Old World strain that causes hemorrhagic fever with renal syndrome (HFRS) — not the Andes virus responsible for the MV Hondius cluster.

Real-world effectiveness data from the Korean military have suggested modest protection from severe HFRS, with antibody titres falling within a year of the primary series. Booster doses are recommended annually in high-risk groups. A WHO position-paper review and several meta-analyses (Hwang et al., 2019) have concluded the protection is real but limited. Hantavax is not used in Europe or the Americas, has never been approved by the FDA or EMA, and would not be expected to protect against Andes virus based on antigenic distance.

3. The NIH/USAMRIID DNA vaccine programme — the most-advanced ANDV candidate

The most-developed candidate specifically against Andes virus is a DNA vaccine encoding the viral glycoprotein Gn/Gc. The programme runs out of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is delivered by intramuscular electroporation, a more efficient method than naked intramuscular injection because it briefly opens cell membranes to accept the plasmid.

Two sister candidates were originally developed in parallel:

• HFRS DNA vaccine (Hantaan + Puumala glycoproteins), which completed phase 2a immunogenicity studies in U.S. servicemembers.
• HPS DNA vaccine (Andes + Sin Nombre glycoproteins), which has completed phase 1 dose-finding studies. The most recent public registration on ClinicalTrials.gov (NCT03682107) described tolerable reactogenicity and detectable neutralising antibodies in most recipients after three doses.

The bottleneck is the absence of a feasible phase 3 efficacy trial. Andes virus generates roughly 100–300 confirmed cases per year across Argentina and Chile combined. Powering a randomised efficacy trial against that incidence would require enrolling tens of thousands of rural Patagonian residents and following them for years — financially and logistically out of reach for a non-pandemic pathogen. The regulatory workaround is the FDA's Animal Rule, which allows licensure based on efficacy demonstrated in well-characterised animal models when human trials are not feasible. Several USAMRIID hantavirus candidates have been positioned for that pathway.

4. mRNA candidates — the post-COVID pivot

Three academic groups (Yale, Oslo, the University of Helsinki) and at least two industry programmes (one disclosed, one undisclosed) have applied the lipid-nanoparticle mRNA platform refined during the COVID-19 pandemic to hantaviruses. The published preclinical data — for example, Hooper et al., 2023 — show robust neutralising antibody responses in non-human primates after a two-dose ANDV-Gn/Gc mRNA series, with cross-reactive protection against Sin Nombre virus.

The strategic argument for an mRNA hantavirus vaccine is not a commercial market — there isn't one — but pandemic preparedness. WHO's R&D Blueprint includes hantaviruses as a priority pathogen family for prototype-vaccine development. The platform can be re-targeted in weeks if a novel hantavirus emerges with broader person-to-person spread, which is precisely the scenario the person-to-person transmission article explains is the watch-list signal for the MV Hondius cluster.

5. Monoclonal antibodies and post-exposure options

Two monoclonal antibodies isolated from convalescent patients (Garrido et al., 2018) have shown protection against ANDV in Syrian-hamster lethal challenge models when administered up to five days post-exposure. These are not vaccines, but they would represent the first targeted post-exposure prophylaxis for hantaviruses if they reach the clinic. As of May 2026 they remain in IND-enabling work; none has been authorised for emergency use during the MV Hondius response.

Convalescent plasma was used in a small Chilean case series in 2019 with apparent benefit, but the evidence is observational and not sufficient to support routine deployment.

6. Why has the pipeline kept stalling?

Three reasons keep recurring across regulatory and policy reviews:

1. Small market. The global at-risk population for severe Andes virus disease is on the order of one million people across rural Patagonia and adjacent Chile. Pharma return-on-investment arithmetic does not work without public funding.
2. No correlate of protection. Unlike measles or influenza, no antibody titre has been shown to reliably predict protection against hantavirus disease. That makes phase 3 design harder.
3. Strain diversity. A vaccine that protects against Andes virus may not protect against Sin Nombre, Seoul, Puumala, or Hantaan, because the surface glycoproteins differ enough that immunity does not generalise. A pan-hantavirus vaccine remains a research goal, not a near-term product.

7. What changes if MV Hondius gets worse?

Realistic regulatory acceleration depends on what happens next. If the cluster stays bounded — fewer than ~60 confirmed cases, no tertiary spread, no genomic divergence — the pipeline returns to its slow pre-pandemic pace. If even one of those signals shifts, the playbook changes. The plausible accelerations are:

• Emergency-use authorisation of an existing DNA or mRNA candidate, targeted at MV Hondius contacts and high-risk Patagonian residents, on the basis of phase 1/2 immunogenicity data.
• A WHO-coordinated phase 3 ring-vaccination trial in Patagonia, on the model of the 2015 Ebola ça-suffit trial.
• Compassionate-use roll-out of a monoclonal antibody for confirmed contacts, contingent on FDA pre-IND meetings the agency has signalled it would expedite.

None of these would be a vaccine in the everyday sense for the next eighteen to twenty-four months. They would be regulatory bridges to buy time while phase 3 efficacy is generated.

8. What this means for travellers and clinicians

For travellers planning trips to Patagonia or considering an expedition cruise, the practical answer is unchanged: there is no vaccine to take, and the cruise-industry biosafety standards are still being rewritten in response to the Hondius cluster. Risk reduction continues to be behavioural — avoid known reservoir habitats, refuse poorly ventilated cabins in rural lodges, follow the rodent-exposure precautions in the rodent-control guide.

For clinicians fielding the question from anxious patients: there is no licensed product, no off-label option that a reasonable evidence-based clinician would recommend, and no regulatory pathway currently open for individual access. Hantavax in Korea does not protect against Andes virus and is not available outside Korea in any case.

Frequently asked questions

Is there a hantavirus vaccine in the United States?

No. The FDA has not approved any hantavirus vaccine. The closest candidate is the USAMRIID DNA vaccine, which has completed phase 1 but not phase 3.

Can I get Hantavax in Korea as a tourist?

It is licensed in Korea for routine use in high-risk occupational groups, primarily military personnel and rural residents. It would not protect against Andes virus and is not generally given to short-term travellers.

Is there a vaccine timeline for Andes virus?

Without acceleration, ten years would be optimistic for a phase 3 result. With Animal Rule licensure of an existing DNA candidate, a regulatory product could exist in 2–4 years; without it, the timeline depends on whether MV Hondius or a successor outbreak triggers a coordinated international funding programme.

What about post-exposure prophylaxis if I was on the ship?

There is no licensed post-exposure prophylaxis. Public-health authorities are tracking exposed individuals for symptoms; the priority is prompt access to ICU-capable care if symptoms develop. See the contact tracing methodology article for what surveillance looks like in practice.

Sources and further reading

• World Health Organization. R&D Blueprint for priority diseases. who.int
• U.S. National Library of Medicine. ClinicalTrials.gov hantavirus search. Live registry of past and ongoing trials.
• Hooper JW, Brocato RL, Kwilas SA et al. DNA vaccines for hantaviruses. Vaccines (Basel), 2023. Open access
• Hwang K-A et al. Effectiveness of an inactivated Hantaan virus vaccine in the Republic of Korea. Vaccine, 2019. (PubMed)
• U.S. Food and Drug Administration. Animal Rule approvals. fda.gov
• Centers for Disease Control and Prevention. Hantavirus — prevention. cdc.gov/hantavirus

Read next

• Why Andes virus is the only hantavirus that spreads between people
• Argentina's hantavirus response — lessons from Epuyén
• Compare hantavirus to other respiratory pathogens
• Argentina country page — current cases and reporting